NASDAQ:AMED Amedisys (AMED) Stock Forecast, Price & News $94.02 +0.10 (+0.11%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$93.50▼$94.2050-Day Range$89.84▼$94.0852-Week Range$69.36▼$107.00Volume196,265 shsAverage Volume521,142 shsMarket Capitalization$3.07 billionP/E Ratio1,343.33Dividend YieldN/APrice Target$109.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amedisys MarketRank™ ForecastAnalyst RatingHold2.23 Rating ScoreUpside/Downside16.6% Upside$109.67 Price TargetShort InterestBearish5.17% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.22Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth2.23%From $4.48 to $4.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 starsMedical Sector748th out of 961 stocksHome Health Care Services Industry5th out of 7 stocks 2.1 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $109.67, Amedisys has a forecasted upside of 16.6% from its current price of $94.02.Amount of Analyst CoverageAmedisys has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.17% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amedisys has recently increased by 20.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 1.8 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amedisys this week, compared to 4 articles on an average week.MarketBeat Follows5 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions95.70% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 2.23% in the coming year, from $4.48 to $4.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 1,343.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 119.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 1,343.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 127.43.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.52. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amedisys (NASDAQ:AMED) StockAmedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMED Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Receives $109.67 Average Target Price from AnalystsSeptember 21, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Now Covered by Analysts at StockNews.comSeptember 25, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 17, 2023 | americanbankingnews.comShort Interest in Amedisys, Inc. (NASDAQ:AMED) Grows By 20.4%September 16, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Price Target Raised to $101.00 at Cantor FitzgeraldSeptember 14, 2023 | markets.businessinsider.comCantor Fitzgerald Maintains Neutral Rating for Amedisys: Here's What You Need To KnowSeptember 14, 2023 | msn.comCantor Fitzgerald Maintains Amedisys (AMED) Neutral RecommendationAugust 15, 2023 | msn.comSignal: UnitedHealth’s Amedisys acquisition under further DOJ scrutinySeptember 25, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 14, 2023 | bizjournals.comTravis Messina named CEO of Regent Surgical HealthJuly 28, 2023 | finance.yahoo.comAmedisys (AMED) Q2 Earnings Beat Estimates, Margins DipJuly 28, 2023 | msn.comCredit Suisse Reiterates Amedisys (AMED) Neutral RecommendationJuly 28, 2023 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About AmedisysJuly 27, 2023 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports Second Quarter 2023 Financial ResultsJuly 27, 2023 | sfgate.comAmedisys: Q2 Earnings SnapshotJuly 27, 2023 | finance.yahoo.comAmedisys Reports Second Quarter 2023 Financial ResultsJuly 27, 2023 | finance.yahoo.comAmedisys (AMED) Tops Q2 Earnings EstimatesJuly 27, 2023 | finance.yahoo.comAmedisys (AMED) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesJuly 19, 2023 | theglobeandmail.comAMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amedisys, Inc. Is Fair to ShareholdersJuly 13, 2023 | seekingalpha.comAmedisys-UnitedHealth And 16 Other Opportunities In The Merger Arbitrage SpaceJuly 12, 2023 | finance.yahoo.comUPDATE 2-Amedisys agrees to $3.3 bln UnitedHealth offer, scraps Option Care dealJuly 10, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Amedisys, Inc. (Nasdaq – AMED)July 6, 2023 | msn.comAmedisys cut to hold at Jefferies as rival bids to UNH unlikelyJuly 6, 2023 | msn.comJefferies Downgrades Amedisys (AMED)June 27, 2023 | msn.comBenchmark Downgrades Amedisys (AMED)June 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Amedisys (AMED)June 27, 2023 | msn.comAmedisys agrees to merge with UnitedHealth, and terminates deal with Option Care HealthSee More Headlines Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Company Calendar Last Earnings7/26/2023Today9/25/2023Next Earnings (Estimated)10/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees20,000Year Founded1982Price Target and Rating Average Stock Price Forecast$109.67 High Stock Price Forecast$165.00 Low Stock Price Forecast$81.00 Forecasted Upside/Downside+16.6%Consensus RatingHold Rating Score (0-4)2.23 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.07 Trailing P/E Ratio1,343.33 Forward P/E Ratio20.99 P/E Growth2.52Net Income$118.61 million Net Margins0.10% Pretax Margin2.18% Return on Equity14.00% Return on Assets7.76% Debt Debt-to-Equity Ratio0.35 Current Ratio0.92 Quick Ratio0.92 Sales & Book Value Annual Sales$2.22 billion Price / Sales1.38 Cash Flow$7.25 per share Price / Cash Flow12.96 Book Value$34.06 per share Price / Book2.76Miscellaneous Outstanding Shares32,630,000Free Float32,046,000Market Cap$3.07 billion OptionableOptionable Beta1.00 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Scott G. Ginn (Age 54)Exec. VP, COO, CFO & Principal Financial Officer Comp: $659.94kMr. Michael P. North (Age 58)Chief Information Officer Comp: $442.38kMs. Denise Bohnert (Age 45)Chief Compliance Officer Comp: $399.72kMr. Nick Muscato (Age 37)Chief Strategy Officer Comp: $400.94kMr. Richard M. Ashworth (Age 48)Pres, CEO & Director Ms. Allyson GuidrozChief Accounting Officer & Principal Accounting OfficerMr. Pete HartleyCTO & Sr. VP of Bus. Operations SystemsMs. Jennifer Guckert GriffinSr. VP, Deputy Gen. Counsel, Corp. Sec. & Interim Chief Legal OfficerKendra KimmonsVP of Marketing & Communications & Media RelationsMr. Adam Holton (Age 52)Chief People Officer More ExecutivesKey CompetitorsChemedNYSE:CHEAddus HomeCareNASDAQ:ADUSAdaptHealthNASDAQ:AHCOOption Care HealthNASDAQ:OPCHLivaNovaNASDAQ:LIVNView All CompetitorsInsiders & InstitutionsBarclays PLCBought 43,293 shares on 9/21/2023Ownership: 0.155%Eubel Brady & Suttman Asset Management Inc.Bought 2,588 shares on 8/25/2023Ownership: 0.008%Alberta Investment Management CorpBought 18,181 shares on 8/24/2023Ownership: 0.056%Comerica BankBought 17,624 shares on 8/22/2023Ownership: 0.054%Osaic Holdings Inc.Bought 208 shares on 8/21/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions AMED Stock - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price forecast for 2023? 13 brokers have issued 12-month price targets for Amedisys' stock. Their AMED share price forecasts range from $81.00 to $165.00. On average, they expect the company's share price to reach $109.67 in the next year. This suggests a possible upside of 16.6% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2023? Amedisys' stock was trading at $83.54 on January 1st, 2023. Since then, AMED stock has increased by 12.5% and is now trading at $94.02. View the best growth stocks for 2023 here. Are investors shorting Amedisys? Amedisys saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,650,000 shares, an increase of 20.4% from the August 15th total of 1,370,000 shares. Based on an average daily volume of 465,500 shares, the short-interest ratio is currently 3.5 days. Currently, 5.2% of the shares of the stock are short sold. View Amedisys' Short Interest. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023. View our AMED earnings forecast. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, July, 26th. The health services provider reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.28. The health services provider earned $552.97 million during the quarter, compared to analyst estimates of $568.18 million. Amedisys had a trailing twelve-month return on equity of 14.00% and a net margin of 0.10%. The business's quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.47 earnings per share. What ETFs hold Amedisys' stock? ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), SRH U.S. Quality ETF (SRHQ), SPDR S&P Health Care Services ETF (XHS) and IQ Merger Arbitrage ETF (MNA).iShares U.S. Healthcare Providers ETF (IHF). What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). What is Amedisys' stock symbol? Amedisys trades on the NASDAQ under the ticker symbol "AMED." Who are Amedisys' major shareholders? Amedisys' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.92%), Riverbridge Partners LLC (4.79%), JPMorgan Chase & Co. (3.36%), Mackenzie Financial Corp (2.89%), State Street Corp (2.85%) and Dimensional Fund Advisors LP (2.21%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amedisys' stock price today? One share of AMED stock can currently be purchased for approximately $94.02. How much money does Amedisys make? Amedisys (NASDAQ:AMED) has a market capitalization of $3.07 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $0.07 on an earnings per share basis. How many employees does Amedisys have? The company employs 20,000 workers across the globe. How can I contact Amedisys? Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163. This page (NASDAQ:AMED) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.